Female founders
International expansion
St Pierre Groupe
Succession planning
OrganOx is a University of Oxford spinout that developed the first fully-automated device for liver preservation. Its technology enables donor livers to be maintained in a functioning state, outside the human body, for up to 24 hours — significantly increasing the number of viable organs available for transplant and improving patient outcomes.
Founded out of the University of Oxford, OrganOx is a pioneering medical technology (medtech) company. Its liver perfusion technology has been used in more than 6,000 liver transplants to date, transforming outcomes for patients worldwide.
We first invested in the business in 2019, and participated in each of the company’s seven funding rounds (as its biggest shareholder). With investment and support from our team, OrganOx was able to scale into a world-leading medtech.
In 2025, we announced the successful exit of OrganOx. The business will continue to operate from Oxford, as a standalone division within global healthcare company Terumo Corporation.
At a $1.5 billion valuation, the exit deal was one of the largest of a UK medtech company to date, and also marked our largest-ever return, generating £175 million of proceeds. It drove a 10x MM on our initial investment, and an overall IRR in the region of 69%.
We’ve already helped hundreds of ambitious businesses in the UK and Ireland to accelerate their growth. If you’re looking for a minority investment partner that can provide long-term, flexible funding and support, please get in touch with our team today.
